(WASHINGTON) FDA REPORT: Approval of the first drug for ‘Alzheimer’s Disease’ in 20yrs that shows substantial evidence that it reducesamyloid beta plaques in the brain” and that this “is reasonably likely to predict important benefits to patients #AceHealthDesk report | Ace News Services

#AceNewsReport – June.09: Aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia, rather than its symptoms:

Source: (WASHINGTON) FDA REPORT: Approval of the first drug for ‘Alzheimer’s Disease’ in 20yrs that shows substantial evidence that it reducesamyloid beta plaques in the brain” and that this “is reasonably likely to predict important benefits to patients #AceHealthDesk report | Ace News Services

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.